newsfilter
← Latest News
Business Wire·

Aptar's Intranasal Delivery System Used in Phase II Clinical Study for Investigational SPONTAN® Nasal Spray

Supporting advancement of complex intranasal therapies through clinical development AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing,